PRESS RELEASE: June 13, 2017

Ben Franklin Technology Partners Invests in NHB


The executive management team of New Horizon Biotechnology (NHB) enthusiastically announced today their relationship with regional impact investors Ben Franklin Technology Partners.

The investment will allow New Horizon Biotechnology to complete testing to demonstrate the effectiveness of a new, proprietary, and patented design for single-use microbial fermentation as compared with designs currently in use. Microbial fermentation is the basis for the production of a wide range of biopharmaceutical products, including antibiotics, vaccines, and therapeutic proteins, among others.

New Horizon Biotechnology (NHB) is a privately held corporation located in Bethlehem, Pennsylvania, USA. NHB has developed and is preparing to deploy a patented fermenter system, SUHF™, that enables more flexible, cost effective, and reproducible production for biotechnology and pharmaceutical customers.